High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.
Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Francesco
F
Marchesi
Pathology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Mariangela
M
Cirillo
Pathology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Antonella
A
Bianchi
Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Michela
M
Gately
Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Odoardo M
OM
Olimpieri
Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Elisabetta
E
Cerchiara
Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Daniela
D
Renzi
IRCCS G.B. Bietti Foundation, Rome, Italy.
Alessandra
A
Micera
IRCCS G.B. Bietti Foundation, Rome, Italy.
Bjorn O
BO
Balzamino
Ophthalmology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Stefano
S
Bonini
Pathology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Andrea
A
Onetti Muda
Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy.
Giuseppe
G
Avvisati
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D015703:Antigens, CD / Q000032:analysis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002452:Cell Count; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D016130:Immunophenotyping; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D008264:Macrophages / Q000737:chemistry / Q000473:pathology*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis*; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D000098902:CD163 Antigen; D000097382:CD68 Molecule
D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D003520:Cyclophosphamide; D004317:Doxorubicin; D011092:Polyethylene Glycols; D011241:Prednisone; D011956:Receptors, Cell Surface; D000069283:Rituximab; D014750:Vincristine; D000098902:CD163 Antigen; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C506643:liposomal doxorubicin